Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2003 1
2007 2
2008 1
2009 2
2010 5
2011 5
2012 3
2013 1
2014 1
2015 4
2016 5
2017 6
2018 6
2019 14
2020 15
2021 13
2022 16
2023 16
2024 23
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for athos c
Search for Atthow C instead (3 results)
Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease.
Garrido-Trigo A, Corraliza AM, Veny M, Dotti I, Melón-Ardanaz E, Rill A, Crowell HL, Corbí Á, Gudiño V, Esteller M, Álvarez-Teubel I, Aguilar D, Masamunt MC, Killingbeck E, Kim Y, Leon M, Visvanathan S, Marchese D, Caratù G, Martin-Cardona A, Esteve M, Ordás I, Panés J, Ricart E, Mereu E, Heyn H, Salas A. Garrido-Trigo A, et al. Nat Commun. 2023 Jul 26;14(1):4506. doi: 10.1038/s41467-023-40156-6. Nat Commun. 2023. PMID: 37495570 Free PMC article.
International consensus on fasting terminology.
Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, Vernieri C, Bloomer RJ, Boschmann M, Bragazzi NL, Brandhorst S, Gabel K, Goldhamer AC, Grajower MM, Harvie M, Heilbronn L, Horne BD, Karras SN, Langhorst J, Lischka E, Madeo F, Mitchell SJ, Papagiannopoulos-Vatopaidinos IE, Papagiannopoulou M, Pijl H, Ravussin E, Ritzmann-Widderich M, Varady K, Adamidou L, Chihaoui M, de Cabo R, Hassanein M, Lessan N, Longo V, Manoogian ENC, Mattson MP, Muhlestein JB, Panda S, Papadopoulou SK, Rodopaios NE, Stange R, Michalsen A. Koppold DA, et al. Cell Metab. 2024 Aug 6;36(8):1779-1794.e4. doi: 10.1016/j.cmet.2024.06.013. Epub 2024 Jul 25. Cell Metab. 2024. PMID: 39059384 Free PMC article.
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice.
Bettenworth D, Baker ME, Fletcher JG, Jairath V, Lu C, Bemelman W, d'Haens G, d'Hoore A, Dignass A, Dotan I, Feakins R, Fleshner P, Ha C, Henderson G, Lyu R, Panes J, Rogler G, Mao R, Rimola J, Sandborn WJ, Ng SC, Siegmund B, Silverberg M, Taylor SA, Verstockt B, Gordon IO, Bruining DH, Feagan BG, Rieder F; Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium. Bettenworth D, et al. Nat Rev Gastroenterol Hepatol. 2024 Aug;21(8):572-584. doi: 10.1038/s41575-024-00935-y. Epub 2024 Jun 3. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38831007 Free PMC article.
ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL.
Chaba A, Zarbock A, Forni LG, Hästbacka J, Korneva E, Landoni G, Pickkers P, Bellomo R. Chaba A, et al. Shock. 2025 Jan 1;63(1):88-93. doi: 10.1097/SHK.0000000000002481. Shock. 2025. PMID: 39671552 Clinical Trial.
Methods: We conducted a post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS) 3 trial which assessed the effect of Intravenous ANG II or placebo in patients with refractory vasodilatory shock in 75 intensive care units across nine countries …
Methods: We conducted a post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS) 3 trial which assessed …
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. Yanai H, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):49-59. doi: 10.1016/S2468-1253(21)00299-5. Epub 2021 Nov 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34739863 Clinical Trial.
Eligible patients were biologic naive adults aged 18-55 years with mild-to-moderate Crohn's disease (defined by a Harvey-Bradshaw Index score of 5-14 points), a maximal disease duration of 5 years, with active disease on colonoscopy, or imaging with elevated inflammatory markers …
Eligible patients were biologic naive adults aged 18-55 years with mild-to-moderate Crohn's disease (defined by a Harvey-Bradshaw Index scor …
Global evolution of inflammatory bowel disease across epidemiologic stages.
Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinović A, Williamson T, Abbey Y, Abdullah M, Abreu MT, Ahuja V, Raja Ali RA, Altuwaijri M, Balderramo D, Banerjee R, Benchimol EI, Bernstein CN, Brunet-Mas E, Burisch J, Chong VH, Dotan I, Dutta U, El Ouali S, Forbes A, Forss A, Gearry R, Dao VH, Hartono JL, Hilmi I, Hodges P, Jones GR, Juliao-Baños F, Kaibullayeva J, Kelly P, Kobayashi T, Kotze PG, Lakatos PL, Lees CW, Limsrivilai J, Lo B, Loftus EV Jr, Ludvigsson JF, Mak JWY, Miao Y, Ng KK, Okabayashi S, Olén O, Panaccione R, Paudel MS, Quaresma AB, Rubin DT, Simadibrata M, Sun Y, Suzuki H, Toro M, Turner D, Iade B, Wei SC, Yamamoto-Furusho JK, Yang SK, Ng SC, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group. Hracs L, et al. Nature. 2025 Jun;642(8067):458-466. doi: 10.1038/s41586-025-08940-0. Epub 2025 Apr 30. Nature. 2025. PMID: 40307548 Free PMC article.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2025 May;15(2_suppl):793S-822S. doi: 10.1177/21925682251336882. Epub 2025 May 21. Global Spine J. 2025. PMID: 40397527 Free PMC article. No abstract available.
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease.
Bezzio C, Franchellucci G, Savarino EV, Mastronardi M, Caprioli FA, Bodini G, Variola A, Scaldaferri F, Furfaro F, Calabrese E, Principi MB, Biscaglia G, Marzo M, Michielan A, Cavalli C, Aratari A, Campigotto M, Ceccarelli L, Cappello M, Saibeni S, Balestrieri P, Soriano A, Casini V, Bertani L, Barberio B, Conforti FS, Danese S, Armuzzi A. Bezzio C, et al. Crohns Colitis 360. 2024 Oct 24;6(4):otae060. doi: 10.1093/crocol/otae060. eCollection 2024 Oct. Crohns Colitis 360. 2024. PMID: 39525291 Free PMC article. No abstract available.
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Feagan BG, et al. Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. Lancet. 2021. PMID: 34090625 Clinical Trial.
159 results